Royalty Pharma: Sandy Lamm LLC proposes $10.3M sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) has a notice of a proposed sale of 150,000 Class A ordinary shares by Sandy Lamm LLC, whose relationship to the issuer is listed as officer. The approximate sale date is November 16, 2026, and the shares have an aggregate market value of $10,278,750. Merrill Lynch is named as the broker. Sandy Lamm LLC acquired the shares from the issuer in a private transaction on June 16, 2020. The sale is made in connection with a selling plan dated August 7, 2026, intended to comply with Rule 10b5-1(c).
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Is Sandy Lamm LLC’s proposed RPRX sale tied to a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.